scholarly journals Fundamental Role of Methylenetetrahydrofolate Reductase 677 C → T Genotype and Flavin Compounds in Biochemical Phenotypes for Schizophrenia and Schizoaffective Psychosis

2016 ◽  
Vol 7 ◽  
Author(s):  
Stephanie Fryar-Williams
2021 ◽  
pp. 112067212110006
Author(s):  
Manuel Marques ◽  
Francisco Alves ◽  
Miguel Leitão ◽  
Catarina Rodrigues ◽  
Joana Tavares Ferreira

The role of polymorphisms of methylenetetrahydrofolate reductase (MTHFR) gene in retinal vein occlusion (RVO) is a theme of discussion since the first reports of RVO in patients with MTHFR C677T mutation and without classic acquired risk factors for retinal vascular disease. The association between MTHFR polymorphisms and RVO has been studied over the last 20 years producing conflicting results. This review aims to summarize the literature concerning the role MTHFR polymorphisms as risk factors for RVO.


Author(s):  
Rosmi Jose ◽  
Venketeswaramurthy N ◽  
Sambath Kumar R

This review describes about the literatures addressing the role of vitamin supplementation in schizophrenia. Evidence is suggesting that vitamin supplementation includes Vitamin A, Vitamin D, Vitamin E, Vitamin B complex, and Vitamin C may be important in treatment. In schizophrenia, patients may have increased level of homocysteine (Hcy), due to the polymorphism in methylenetetrahydrofolate reductase and hypofunction of N-methyl-D-aspartate receptors. The vitamins main effects are reduced the Hcy level and maintain dopamine and serotonin levels. Add-on treatment with high-dose B vitamins including B6, B9, and B12 and also Vitamin D can significantly reduce symptoms of schizophrenia more than standard treatments alone.


2011 ◽  
Vol 26 (3) ◽  
pp. 318-321 ◽  
Author(s):  
Hamza Alsayouf ◽  
Khaled M. Zamel ◽  
Geoffrey L. Heyer ◽  
A. Latif Khuhro ◽  
Samir B. Kahwash ◽  
...  

2013 ◽  
Vol 41 (2) ◽  
pp. 573-579 ◽  
Author(s):  
Hena Naqvi ◽  
Syed Rizwan Hussain ◽  
Mohammad Kaleem Ahmad ◽  
Farzana Mahdi ◽  
Shyam Pyari Jaiswar ◽  
...  

2020 ◽  
pp. 1-12
Author(s):  
Dimitra Liapi ◽  
Aikaterini Sfiridaki ◽  
Aikaterini Livadiotaki ◽  
Athanasios Alegakis ◽  
Kostas Stylianou ◽  
...  

<b><i>Background:</i></b> The inherited thrombophilic mutations of the factor V gene (FVG1691A Leiden-FVL), prothrombin gene (PTG20210A), and the methylenetetrahydrofolate reductase gene C677T (MTHFR C677T) are risk factors for thromboembolic events and are related to the pathogenesis of vascular diseases. <b><i>Objectives:</i></b> The main objective of this study was to explore the role of these factors in the pathogenesis of chronic kidney disease (CKD) and survival of patients with CKD-5 receiving haemodialysis. <b><i>Methods:</i></b> A cohort of 395 patients with CKD-5 on haemodialysis, from 6 dialysis units in Crete, Greece were recruited based on their medical records and were followed for 5 years. We collected data on CKD-5 aetiology, thrombophilic gene expression, vascular access thrombosis, time of death, and causes of death. <b><i>Results:</i></b> The mutated genes just as prevalent in patients with CKD-5 as they were in a control group with no renal disease (<i>p</i> &#x3e; 0.05). FVL heterozygosity was significantly more prevalent (11.4 vs. 5.7%; <i>p</i> = 0.036) in patients presented with CKD of unknown aetiology, compared to CKD secondary to known aetiologies. The survival of patients with CKD-5 receiving haemodialysis was not affected by the presence of any thrombophilic mutation. This held true for the whole cohort and for the cohort that included only lethal vascular events. Most patients with MTHFR C677T heterozygosity, and all patients with MTHFR C677T homozygosity, died from vascular events during the follow-up period. <b><i>Conclusion:</i></b> The FVL mutation may act as a risk factor for CKD. This study increases our understanding of molecular mechanisms in the pathogenesis of CKD of unknown aetiology. Τhe presence of thrombophilic mutations did not affect the overall survival of patients with CKD-5. This finding probably reflects the effect of medical care on patient outcomes.


2002 ◽  
Vol 134 (1) ◽  
pp. 57-61 ◽  
Author(s):  
Martin Weger ◽  
Olaf Stanger ◽  
Hannes Deutschmann ◽  
Franz Josef Leitner ◽  
Wilfried Renner ◽  
...  

2009 ◽  
Vol 33 (7) ◽  
pp. 1009
Author(s):  
Crisiane Wais Zanrosso ◽  
Ana Hatagima ◽  
Mariana Emerenciano ◽  
Flávio Ramos ◽  
Alexandre Figueiredo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document